FindTrial
Sign In

How the main breathing muscle moves after giving an initial dose of a commonly used medicine (magnesium sulphate) to very sick pregnant women with high blood pressure

Assessment of diaphragmatic excursion following administration of intravenous loading dose of magnesium sulphate in parturients having preeclampsia with severe features - A prospective, observational trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/107538
Enrollment
30
Registered
2026-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O141- Severe pre-eclampsia

Interventions

Intervention1: Nil: Nil

Sponsors

Post-Graduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Thirty consenting parturients (aged 18 years and above) having preeclampsia with severe features who will be receiving intravenous magnesium sulphate loading dose (4g).

Exclusion criteria

Exclusion criteria: 1.Neuromuscular disorders (myasthenia gravis, muscular dystrophies, motor neuron disease, peripheral neuropathies) 2.Baseline diaphragmatic dysfunction (diaphragmatic excursion less than 10 mm by ultrasonography), 3.Poor USG view (like in obesity, excess bowel gas, anatomic variations, patient discomfort or inability to cooperate) 4.Any contraindication to the administration of magnesium sulphate, 5.Pre-existing severe cardiovascular, renal, pulmonary diseases.

Design outcomes

Primary

MeasureTime frame
To measure the change in diaphragmatic excursion in parturients having preeclampsia with severe features.Timepoint: Before and 30 minutes following administration of intravenous loading dose of magnesium sulphate (4g).—

Secondary

MeasureTime frame
To assess correlation between the diaphragmatic excursions and the serum magnesium levels.Timepoint: Before and 30 minutes following administration of intravenous loading dose of magnesium sulphate (4g).;To assess change in the vital parameters (respiratory rate, oxygen saturation, mean blood pressure, heart rate and NYHA class)Timepoint: Before and 30 minutes following administration of intravenous loading dose of magnesium sulphate (4g).;Modification of standard Lung ultrasound scoring systemTimepoint: Before and 30 minutes following administration of intravenous loading dose of magnesium sulphate (4g).;To examine auscultatory findings of respiratory and cardiovascular systemTimepoint: Before and 30 minutes following administration of intravenous loading dose of magnesium sulphate (4g).—

Countries

India

Contacts

Public ContactDr Medaker Shisha R Syiem

Post-Graduate Institute of Medical Education and Research

dr.komalgandhi@yahoo.com7087003376

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026